Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia

Interleukin-8 在良性前列腺增生中的诱导生物学作用

基本信息

  • 批准号:
    7780559
  • 负责人:
  • 金额:
    $ 39.13万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-09-01 至 2014-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Benign prostatic hyperplasia (BPH) is typified by epithelial and stromal hyperplasia and progressive enlargement of the prostate gland. BPH is associated with chronic inflammation, however specific mechanisms are unknown. We have reported that hyperplastic BPH epithelium overexpresses interleukin-8 (IL-8) and that this correlated significantly with a myofibroblast reactive stroma phenotype with altered expression patterns of tenascin. IL-8 is a potent chemokine that induces chemotaxis of marrow-derived cells and stimulates reactive stroma / wound repair mechanisms. We have generated a human xenograft model that overexpresses IL-8 and transgenic mouse lines expressing KC (a murine homolog of IL-8) and observe a hyperplastic epithelial and reactive stroma phenotype induced by IL-8(KC) with elevated tenascin-C and pro- collagen I. Our preliminary data suggests that reactive stroma may be recruited from circulating marrow- derived progenitor fibrocyte (CD14+) cells. It is our hypothesis that elevated IL-8 functions to activate and/or recruit reactive stroma progenitor cells at foci of glandular BPH and that this hyperplastic reactive stroma further drives BPH glandular and stromal hyperplasia. To address this hypothesis three Specific Aims are proposed: 1. To characterize the role of IL-8(KC) / CXCR2 signaling and tenascin-C, as a downstream effector, in the induction of prostate hyperplasia. 2. To determine the role of IL-8 / CXCR2 receptor signaling in the recruitment of reactive stroma progenitor cells. 3. To target IL-8(KC) / CXCR2 signaling in reactive stroma cells using drug-inducible gene expression to uncouple signaling and therefore attenuate the genesis of reactive stroma and epithelial hyperplasia in BPH. The purpose of this project is to determine basic mechanisms of IL-8 action in recruiting reactive stroma and establish proof-of-concept that reactive stroma progenitor cells and subsequent reactive stroma can be targeted to uncouple key pathways in order to attenuate the hyperplastic phenotype. PUBLIC HEALTH RELEVANCE: This objective of this study is to determine how interleukin-8 (IL-8) regulates the biology of benign prostatic hyperplasia. This project will provide data on key mechanisms and pathways using several model systems. These mechanisms and pathways may evolve as therapeutic targets.
描述(由申请人提供):良性前列腺增生(BPH)的典型特征是前列腺上皮和间质增生以及进行性增大。BPH与慢性炎症有关,但具体机制尚不清楚。我们已经报道了增生的BPH上皮细胞过度表达白细胞介素-8(IL-8),这与腱生蛋白表达模式改变的肌成纤维细胞反应性基质表型显著相关。IL-8是一种有效的趋化因子,可诱导骨髓源性细胞的趋化性并刺激反应性基质/伤口修复机制。我们已经产生了过表达IL-8的人异种移植物模型和表达KC(IL-8的鼠同源物)的转基因小鼠系,并观察到由IL-8(KC)诱导的增生性上皮和反应性基质表型以及升高的生腱蛋白-C和前胶原I。我们的初步数据表明,反应性基质可能是从循环的骨髓来源的祖纤维细胞(CD 14+)细胞。我们的假设是,升高的IL-8的功能是激活和/或募集腺性BPH病灶处的反应性基质祖细胞,并且这种增生的反应性基质进一步驱动BPH腺和基质增生。为了解决这一假设,提出了三个具体目标:1。研究IL-8(KC)/CXCR 2信号通路和作为下游效应物的生肿蛋白-C在前列腺增生诱导中的作用。2.确定IL-8 /CXCR 2受体信号在反应性基质祖细胞募集中的作用。3.使用药物诱导基因表达靶向反应性基质细胞中的IL-8(KC)/CXCR 2信号传导,以解偶联信号传导,从而减弱BPH中反应性基质和上皮增生的发生。该项目的目的是确定IL-8在募集反应性基质中作用的基本机制,并建立概念验证,即反应性基质祖细胞和随后的反应性基质可以靶向解偶联关键途径,以减弱增生表型。 公共卫生相关性:本研究的目的是确定白细胞介素-8(IL-8)如何调节良性前列腺增生的生物学。该项目将使用几个模型系统提供关于关键机制和途径的数据。这些机制和途径可能演变为治疗靶点。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DAVID R ROWLEY其他文献

DAVID R ROWLEY的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DAVID R ROWLEY', 18)}}的其他基金

Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
骨转移进展和内分泌抵抗中的成骨生态位生物学
  • 批准号:
    10474332
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
骨转移进展和内分泌抵抗中的成骨生态位生物学
  • 批准号:
    10231044
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
Osteogenic Niche Biology in Progression and Endocrine Resistance of Bone Metastases
骨转移进展和内分泌抵抗中的成骨生态位生物学
  • 批准号:
    10001465
  • 财政年份:
    2018
  • 资助金额:
    $ 39.13万
  • 项目类别:
SUMMER UNDERGRADUATE RESEARCH FELLOWSHIP PROGRAM
夏季本科生研究奖学金计划
  • 批准号:
    8360067
  • 财政年份:
    2011
  • 资助金额:
    $ 39.13万
  • 项目类别:
SUMMER UNDERGRADUATE RESEARCH FELLOWSHIP PROGRAM
夏季本科生研究奖学金计划
  • 批准号:
    8167603
  • 财政年份:
    2010
  • 资助金额:
    $ 39.13万
  • 项目类别:
Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
Interleukin-8 在良性前列腺增生中的诱导生物学作用
  • 批准号:
    8543714
  • 财政年份:
    2010
  • 资助金额:
    $ 39.13万
  • 项目类别:
Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
Interleukin-8 在良性前列腺增生中的诱导生物学作用
  • 批准号:
    8322849
  • 财政年份:
    2010
  • 资助金额:
    $ 39.13万
  • 项目类别:
Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
Interleukin-8 在良性前列腺增生中的诱导生物学作用
  • 批准号:
    8089342
  • 财政年份:
    2010
  • 资助金额:
    $ 39.13万
  • 项目类别:
SUMMER UNDERGRADUATE RESEARCH PROGRAM AT BROWN UNIVERSITY
布朗大学暑期本科生研究项目
  • 批准号:
    7960155
  • 财政年份:
    2009
  • 资助金额:
    $ 39.13万
  • 项目类别:
Interleukin-8 Induced Biology in Benign Prostatic Hyperplasia
Interleukin-8 在良性前列腺增生中的诱导生物学作用
  • 批准号:
    7935051
  • 财政年份:
    2009
  • 资助金额:
    $ 39.13万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.13万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了